Actively Recruiting
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Led by Medical University of Lublin · Updated on 2024-06-03
50
Participants Needed
1
Research Sites
382 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues. Bones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.
CONDITIONS
Official Title
Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age > 18 years
- Mastocytosis defined according to WHO criteria
- Known KIT mutation status
You will not qualify if you...
- History of organ transplant
- Inability to give informed consent
- Pregnancy, Breastfeeding
- Vulnerable patient defined as having another uncontrolled severe disease or being under juridical protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Hematooncology and Bone Marrow Transplantation
Lublin, Lublin Voivodeship, Poland, 20-081
Actively Recruiting
Research Team
A
Aneta Szudy-Szczyrek, MD., PhD.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here